197 research outputs found

    Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship

    Get PDF
    Public interest in approaches that might provide prescription drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. In the current debate, some argue that the government’s financial, scientific, and/or clinical support of health-related research and development (R&D) entitles the public to commensurate considerations in the prices charged for any resulting drugs. Others view government intervention in price decisions based upon initial federal funding as contrary to a long-term trend of government promotion of innovation, technological advancement, and the commercialization of technology by the business community leading to new products and processes for the marketplace. The government traditionally funds R&D to meet the mission requirements of the federal departments and agencies. It also supports work in areas where there is an identified need for research, primarily basic research, not being performed in the private sector. Over the past 25 years, congressional initiatives have expanded the government’s role to include the promotion of technological innovation to meet other national needs, particularly the economic growth that flows from the use of new and improved goods and services. Various laws facilitate commercialization of federallyfunded R&D through technology transfer, cooperative R&D, and intellectual property rights. The legislated incentives are intended to encourage additional private sector investments often necessary to further develop marketable products. The current approach to technology development attempts to balance the public sector’s interest in new and improved technologies with concerns over providing companies valuable benefits without adequate accountability or compensation. Some question whether or not the current balance is appropriate, particularly with respect to drug discovery. The particular nature and expense of health-related R&D has focused attention on the manner in which the National Institutes of Health (NIH) undertakes research activities. Critics maintain that the need for technology development incentives in the pharmaceutical and/or biotechnology sectors is mitigated by industry access to government-supported work at no cost, monopoly power through patent protection, and additional regulatory and tax advantages such as those conveyed through the Hatch-Waxman Act and the Orphan Drug Act. Supporters of the existing approach argue that these incentives are precisely what are required and have given rise to robust pharmaceutical and biotechnology industries. It remains to be seen whether or not decisions related to federal involvement in issues related to pharmaceutical R&D will change the nature of the current approach to government-industry-university cooperation. This report will be updated as events warrant

    The National Institute of Standards and Technology: An Overview

    Get PDF
    The National Institute of Standards and Technology (NIST) has a mandate to increase the competitiveness of U.S. firms and provide the measurement, calibration, and quality assurance techniques that underpin U.S. commerce. Congressional debate has focused on the merits of NIST’s external R&D programs directed toward increased private sector commercialization, including the Advanced Technology Program (ATP) and the Manufacturing Extension Partnership (MEP). The level of funding for internal research efforts has also been scrutinized by Congress. FY2006 appropriations legislation provided 752millionforNIST,anincreaseof8.2752 million for NIST, an increase of 8.2% over FY2005 (after mandated rescissions) and financed ATP, although at a reduced rate, despite the President’s budget and the original House-passed bill that included no support for the program. While no final FY2007 appropriations legislation was enacted during the 109th Congress, a series of continuing resolutions financed NIST at FY2006 levels through February 15, 2007. In the current Congress, P.L. 110-5 provides NIST with 675 million for FY2007. The President’s FY2008 budget request for NIST totals $640.7 million and includes a significant cut in support for MEP and no funding for ATP. This report will be updated as events warrant

    The National Institute of Standards and Technology: An Overview

    Get PDF
    The National Institute of Standards and Technology (NIST) has a mandate to increase the competitiveness of U.S. firms and provide the measurement, calibration, and quality assurance techniques that underpin U.S. commerce. Congressional debate has focused on the merits of NIST’s external R&D programs directed toward increased private sector commercialization, including the Advanced Technology Program (ATP) and the Manufacturing Extension Partnership (MEP). The level of funding for internal research efforts has also been scrutinized by Congress. FY2006 appropriations legislation provided 752millionforNIST,anincreaseof8.2752 million for NIST, an increase of 8.2% over FY2005 (after mandated rescissions) and financed ATP, although at a reduced rate, despite the President’s budget and the original House-passed bill that included no support for the program. While no final FY2007 appropriations legislation was enacted during the 109th Congress, a series of continuing resolutions financed NIST at FY2006 levels through February 15, 2007. In the current Congress, P.L. 110-5 provides NIST with 675 million for FY2007. The President’s FY2008 budget request for NIST totals $640.7 million and includes a significant cut in support for MEP and no funding for ATP. This report will be updated as events warrant
    • 

    corecore